Veliparib (ABT-888)

Catalog No.S1004 Synonyms: NSC 737664

Veliparib (ABT-888) Chemical Structure

Molecular Weight(MW): 244.29

Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.

Size Price Stock Quantity  
In DMSO USD 156 In stock
USD 120 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 40 Publications

9 Customer Reviews

  • (A) OVCAR-8 cells were exposed to the indicated concentrations of FdUrd along with vehicle, 3 μM ABT-888 or 300 nM AZD2281 for 24 h. Following washing, ABT-888 and AZD2281 were re-added to the plates initially exposed to these agents, and cells were cultured in the continued presence of ABT-888 and AZD2281 for 8 d until colonies formed. (B) OVCAR-8 cells were exposed continuously to the indicated agents for 8 d. (C) OVCAR-8 cells treated as in (A) except that the indicated concentrations of ABT-888 were used.

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

    OVCAR-8 cells were plated, treated with indicated concentrations of FdUrd and 3 μM ABT-888 using the exposure schemes depicted in (C) and assayed for clonogenicity (D).

    Cancer Research, 2011, 71: 4944-4954. Veliparib (ABT-888) purchased from Selleck.

  •  

    Number of foci detected using laser confocal microscopy and fluorescent Fluor 647 anti-H2A.X-phosphorylated (Ser139) antibody. Double-stranded breaks (red) are clearly augmented in cells incubated with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281 compared with PBS and 1% dimethyl sulfoxide controls. Image analysis was performed using ImageJ and the ‘analyze particle’ function.

    Nucl Med Commun 2011 32, 1046-1051. Veliparib (ABT-888) purchased from Selleck.

    Logarithmic growth curves of human Burkitt lymphoma cells over 5 days with 500 nmol/l of ABT-888 and AZD-2281 in combination with 0 Gy (a), 4 Gy (b), 8 Gy (c), and 12 Gy (d) of external beam radiation. The maximal relative reduction was 65.5% of viable cells and occurred with AZD-2281 (500 nmol/l) on day 5. DMSO, dimethyl sulfoxide.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

  • Colorimetric poly(ADP-ribose) polymerase (PARP) activity assay showing the relative activity of the PARP-1 enzyme in Raji lymphocyte tumor cells. Results show a highly significant difference in PARP activity in the controls [PBS and dimethyl sulfoxide (DMSO)] compared with 24 h incubation with 500 nmol/l of ABT-888 and 500 nmol/l of AZD-2281. A significant increase in PARP enzyme activity is shown in DMSO-incubated cells compared with PBS control.* P < 0.05.

    Nucl Med Commun 2011 32(11), 1046-51. Veliparib (ABT-888) purchased from Selleck.

    T47D breast cancer cells were pretreated with indicated concentrations of ABT-888

     

     

    Dr.Zhang of Tianjin Medical University. Veliparib (ABT-888) purchased from Selleck.

  • in vivo suppression of PAR formation by the PARP inhibitor ABT-888 upon induction of DNA damage

    Primary human lung fibroblast cells (MRC-5) were pre-treated with the indicated concentration of the PARP inhibitor ABT-888 for two hours. Oxidative DNA damage was induced by 500 µM H2O2 for 10 min and cellular PARP activity was measured by immuno-staining of poly(ADP)-ribose (PAR) (right panels). The in vivo effect of PARP inhibition was compared to cells without DNA damage induction and inhibitor (control) and H2O2-treated cells without inhibitor.
    Average nuclear PAR staining intensities of more than 50 cells were statistically analysed by Kruskal-Wallis and the post-hoc Dunn’s Multiple Comparison tests (left panel). Asterisks indicate highly significant (p<1%) differences to H2O2-treated cells without PARP inhibitor. Thick horizontal bars mark medians and error bars the interquartile range.
     
     

     

    David Schrmann from University of Base. Veliparib (ABT-888) purchased from Selleck.

    Caption:  451 Lu is a melanoma cell line with high PARP expression that is resistant to temozolomide.  Treatment with 25 µM ABT-888 greatly increased sensitivity to temozolomide compared to cells without ABT-888 treatment as measured by MTS assay.

     

     

    Dr. Steve Reuland from University of Colorado Denver. Veliparib (ABT-888) purchased from Selleck.

  • Effect of ABT-888 on the viability of endometrial cancer cell line Hec50 and Ishikawa and ovarian cancer cell line SKOV3,Caov3 and PA-1 was detected by WST-1 method after 3 days treatment.

     
     

     

    Dr. Xiangbing Meng of University of Iowa. Veliparib (ABT-888) purchased from Selleck.

Purity & Quality Control

Choose Selective PARP Inhibitors

Biological Activity

Description Veliparib (ABT-888) is a potent inhibitor of PARP1 and PARP2 with Ki of 5.2 nM and 2.9 nM in cell-free assays, respectively. It is inactive to SIRT2. Phase 3.
Features Increases the efficacy of common cancer therapies such as radiation and alkylating agents.
Targets
PARP2 [1]
(Cell-free assay)
PARP1 [1]
(Cell-free assay)
2.9 nM(Ki) 5.2 nM(Ki)
In vitro

ABT-888 is inactive to SIRT2 (>5 μM). [1] ABT-888 inhibits the PARP activity with EC50 of 2 nM in C41 cells. [2] ABT-888 could decrease the PAR levels in both irradiated and nonirradiated H460 cells. ABT-888 also reduces clonogenic survival and inhibits DNA repair by PARP-1 inhibition in H460 cells. ABT-888 increases apoptosis and autophagy in H460 cells when combination with radiation. [3] ABT-888 also inhibits PARP activity in H1299, DU145 and 22RV1 cells and the inhibition is independent of p53 function. ABT-888 (10 μM) suppresses the surviving fraction (SF) by 43% in the clonogenic H1299 cells. ABT-888 shows effective radiosensitivity in oxic H1299 cells. Furthermore, ABT-888 could attenuate the SF of hypoxic-irradiated cells including H1299, DU145 and 22RV1. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
C41 NXjzOodyU2mwYYPlJGF{e2G7 MXWzNEBucW5? MoP4TY5pcWKrdHnvckBw\iCSQWLQNUB4cXSqIFXDOVAhd2ZiMD6wNFIh|ryP NX7TOlZ1OTl6OEi3OlA>
Jurkat M4fDU2tqdmG|ZTDBd5NigQ>? MXS5OkBp MULEUXNQ NUDzeGhXUW6qaXLpeIlwdiCxZjDQRXJROSCjc4Pld5Nm\CCjczDy[YR2[3Srb36gc4Yh[2WubDD2bYFjcWyrdImge4l1cCCHQ{WwJI9nKDNizszN M4fxRlI{QDVyMUm5
Capan1 NInjb3VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHzWWQ4OiCq MoLSSG1UVw>? NGD4[FZCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JGJTS0F{IHflcoUhdXW2YYTl[EBpfW2jbjDDZZBidjFiY3XscJMhf2m2aDDJR|UxKG:oIEO5Mlch|ryP MXeyOFM6QDN6Mx?=
DT40 NIPCV3hEgXSxdH;4bYMhSXO|YYm= NICxbnI4OiCq NV3NWGZDTE2VTx?= NGiwXolEgXSxdH;4bYNqfHliYXfhbY5{fCClaHnjb4VvKEKUQ1GyMYRm\mmlaXXueEBFXDRyIHPlcIx{ Ml34NlQ6OjJ3OEe=
ML-1 MXzBdI9xfG:2aXOgRZN{[Xl? M1;pXVIvPSEQvF2= NVzGUIpbOjRiaB?= MVvEUXNQ MkjhV5lv\XKpaYP0bYNidGy7IHXubIFv[2W|IGTSRWlNNWmwZIXj[YQh[XCxcITvd4l{KGmwIF3MMVEh[2WubIO= MYqyOFg6PTF|NR?=
HCT-116 MX7LbY5ie2ViQYPzZZk> MnzJNE42KM7:TR?= M1f6N|I1KGh? NGCye2pRSVKSIHHjeIl3cXS7IHTlZ5Jm[XOncx?= NH;F[5UzOzB3NEKxNy=>
UM-SCC1 M2S4XWN6fG:2b4jpZ{BCe3OjeR?= NETTdWkyOCEQvF2= MlPzNlQhcA>? NVLuc5FxWmWmdXPld{B1cGViY3XscEB3cWGkaXzpeJk> MnXaNlE6OTJ4MkC=
FaDu M{fnXmN6fG:2b4jpZ{BCe3OjeR?= M3\sV|ExKM7:TR?= M3P6elI1KGh? MV7S[YR2[2W|IITo[UBk\WyuII\pZYJqdGm2eR?= NEHjb2ozOTlzMk[yNC=>
PC-3 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUCxNEDPxE1? MWDJcoR2[2W|IHGgd4lodmmoaXPhcpQhcW6qaXLpeIlwdiCrbjDjc4xwdnliZn;ycYF1cW:wwrC= M1rPTlIyPTdzOUGy
EoL-1-cell NV\HOWZCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlvDTWM2OD1zLkC3PVgh|ryP MVrTRW5ITVJ?
NCI-SNU-5 NFq2UFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MonDTWM2OD1|LkGyPFQyKM7:TR?= M2fFeXNCVkeHUh?=
BV-173 M4DyXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGDvVpdKSzVyPUWuOFU1ODlizszN M2nndnNCVkeHUh?=
HCC1806 NInKNYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\RSXlyUUN3ME21Mlc2OTd|IN88US=> NF\V[HBUSU6JRWK=
COLO-680 NFXJSWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTZwMkG0NFYh|ryP M{HuUnNCVkeHUh?=
HCC2218 NF\3flRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTdwN{m3NFQh|ryP NFW5bIRUSU6JRWK=
SK-MEL-24 NWLMe2xLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\BfGlEPTB;Nz64NVkzPCEQvF2= NHvYUVlUSU6JRWK=
NCI-H720 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;uO5VjUUN3ME24MlQ{PjB|IN88US=> NUewZZZnW0GQR1XS
KASUMI-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUTJR|UxRThwOEmyOlYh|ryP NUjQO441W0GQR1XS
HAL-01 NELmZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4SxfWlEPTB;OT64PFYzKM7:TR?= MkPsV2FPT0WU
CAL-33 M1SxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXzSRotFUUN3ME2xNE41OzRizszN MVvTRW5ITVJ?
SK-MEL-1 NETXblRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnBTWM2OD1zMj60OlY{KM7:TR?= Ml3lV2FPT0WU
Ramos-2G6-4C10 NXnsNZJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVzJR|UxRTF{LkS3OVIh|ryP NF24RXNUSU6JRWK=
KY821 NYHZc3pMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWXJR|UxRTF{LkS4OUDPxE1? M{nFTHNCVkeHUh?=
HEC-1 NEPIbI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;tRZhKSzVyPUGyMlkyQTZizszN MojGV2FPT0WU
SK-NEP-1 MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoK1TWM2OD1zMz6xOlYh|ryP NYTvUHVVW0GQR1XS
MN-60 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mom4TWM2OD1zMz61N|g6KM7:TR?= NEn5NItUSU6JRWK=
DU-145 NGXaRWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e4SWlEPTB;MUOuPVA2OyEQvF2= MmXqV2FPT0WU
EW-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\JUndMUUN3ME2xOE42PTZ3IN88US=> MnPUV2FPT0WU
OS-RC-2 M3:zNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnFW|ROUUN3ME2xOU46PTh7IN88US=> M1HvbnNCVkeHUh?=
RPMI-8226 NHHycpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXq5Uo9FUUN3ME2xOk4zODR{IN88US=> NWTXW5JoW0GQR1XS
ChaGo-K-1 M2\JfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTF4LkWzNlUh|ryP NETVUJVUSU6JRWK=
DEL MmG4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkLUTWM2OD1zNj62O|E4KM7:TR?= MVHTRW5ITVJ?
GP5d NED3WY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3pN4tKSzVyPUG3MlA2OyEQvF2= MVPTRW5ITVJ?
COLO-668 NYfodGJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjmTWM2OD1zNz62Nlk1KM7:TR?= NYjBO5JZW0GQR1XS
H9 NEnHSIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlzyTWM2OD1zOD6yPFM{KM7:TR?= NYfxe4ZlW0GQR1XS
NKM-1 MoPLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV7WTHZOUUN3ME2xPE42OTF7IN88US=> Mli5V2FPT0WU
KYSE-150 M2Gxd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TycmlEPTB;MUiuPVk5PiEQvF2= NWrj[5lxW0GQR1XS
Daoy M1r0SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{GwUWlEPTB;MUmuOVY1QSEQvF2= Ml3hV2FPT0WU
ECC10 NIrCUppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrDRZJKSzVyPUKwMlc1PTVizszN NYG4SFF{W0GQR1XS
A388 M1\xS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fUTmlEPTB;MkGuPVA6OSEQvF2= M1LZTnNCVkeHUh?=
MHH-NB-11 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M17oS2lEPTB;MkOuNVM3OyEQvF2= MlXPV2FPT0WU
HCC1937 MkXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLxW2t[UUN3ME2yOE44PDZizszN NYjuUVlNW0GQR1XS
TGBC11TKB MmHHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF[2NpZKSzVyPUK1MlY5PjNizszN NXn5[pI1W0GQR1XS
CTV-1 NWTuVYN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MljrTWM2OD1{NT64PVY6KM7:TR?= NWL6PI5GW0GQR1XS
NCI-H2029 NFS3eZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTJ4LkSyN|gh|ryP NXu2OHV[W0GQR1XS
HLE MmTFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{S4VWlEPTB;MkeuNFU1KM7:TR?= NFzqc4ZUSU6JRWK=
NCI-H1693 MkXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTVTWM2OD1{Nz6yPFk5KM7:TR?= NHPMVWpUSU6JRWK=
HCC70 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzIcolKSzVyPUK3MlczPDZizszN MYXTRW5ITVJ?
BEN NETodZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTJ5Lkm1OlYh|ryP NYeyO3R[W0GQR1XS
LB771 NELzUVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfqT5dKSzVyPUK4Mlg{PzNizszN MYfTRW5ITVJ?
697 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV64[lM1UUN3ME2yPU4xOjN3IN88US=> NWHSeoY1W0GQR1XS
LU-139 NUnNO2x3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjk[YhKSzVyPUK5MlM4PDhizszN MV\TRW5ITVJ?
EW-13 M2\iOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\ITWM2OD1{OT6zPFE1KM7:TR?= MY\TRW5ITVJ?
MOLT-13 NFjKfmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIezVZhKSzVyPUK5MlM5OTRizszN NVjkN48xW0GQR1XS
L-363 NUXLb25qT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;p[XRlUUN3ME2yPU41Pzl6IN88US=> MnmzV2FPT0WU
EM-2 MmD4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXv1RWlxUUN3ME2yPU41QTBzIN88US=> MWLTRW5ITVJ?
RS4-11 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLuWIQ5UUN3ME2zNE41OjRzIN88US=> NWq4eVZDW0GQR1XS
A2780 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnr5TWM2OD1|MD63OFU4KM7:TR?= Ml76V2FPT0WU
KU812 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTN{LkO2OFIh|ryP MlfXV2FPT0WU
COLO-684 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HJNWlEPTB;M{OuN|U6QSEQvF2= MUTTRW5ITVJ?
MFE-280 NVXENlJPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHjXZF4UUN3ME2zN{4{QDh7IN88US=> MW\TRW5ITVJ?
KG-1 MnrqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXH1Nm9pUUN3ME2zN{43ODBzIN88US=> NVj6[4JXW0GQR1XS
JVM-3 NWq0R45wT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHlTWM2OD1|NT61PFY5KM7:TR?= M3W4PXNCVkeHUh?=
MV-4-11 NHXVUWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDXSXNTUUN3ME2zOU45PDl7IN88US=> NEL1XnBUSU6JRWK=
LAMA-84 MnriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmmyTWM2OD1|Nj63N|Q2KM7:TR?= NHHLVG1USU6JRWK=
MOLT-16 M1zwO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTN4Lkm1NkDPxE1? Mlq5V2FPT0WU
H4 NIfTTolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHhTWM2OD1|Nz61Olch|ryP MWTTRW5ITVJ?
T47D NGXL[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX6zeWlqUUN3ME2zO{44ODF6IN88US=> NUHlPI94W0GQR1XS
CAL-54 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn3TWM2OD1|Nz65OlYh|ryP M3S1N3NCVkeHUh?=
SW982 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{HhNWlEPTB;M{iuNFk6QCEQvF2= NUTINYFRW0GQR1XS
IGROV-1 NXLUbmY3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTN7LkOzNFQh|ryP MnrHV2FPT0WU
NB14 Mo\kS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2juN2lEPTB;NECuO|A{OSEQvF2= NYXVT4xrW0GQR1XS
HCC1187 NHS3d5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUPJR|UxRTRzLkK3O|Eh|ryP M1;OOHNCVkeHUh?=
SBC-1 NUjLNVhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPzZ3hKSzVyPUSxMlMxPjNizszN Mk\JV2FPT0WU
KARPAS-45 M3TBNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTRzLkS4NVgh|ryP MUDTRW5ITVJ?
MOLT-4 Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjtbllKSzVyPUSyMlI2OzhizszN NUnadpJHW0GQR1XS
JVM-2 MlqwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmfJTWM2OD12Mj65NlA4KM7:TR?= NYjBfGNbW0GQR1XS
A4-Fuk NXezVFNET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TmeWlEPTB;NEOuOVY6OSEQvF2= M3The3NCVkeHUh?=
MDA-MB-361 MmHXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTR|Lki0NVQh|ryP MUXTRW5ITVJ?
BALL-1 MonzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1XNfmlEPTB;NEOuPVU{OiEQvF2= M{TjV3NCVkeHUh?=
T98G MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\FdG5KSzVyPUS0Mlg2OTdizszN NYPzfYx3W0GQR1XS
Mo-T MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1viVGlEPTB;NEWuOlM5QSEQvF2= M3fJU3NCVkeHUh?=
MHH-PREB-1 MnL2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mk\wTWM2OD12NT63OVg2KM7:TR?= M{jBOHNCVkeHUh?=
ALL-PO MkXES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIHodHFKSzVyPUS3MlM4QTFizszN MWnTRW5ITVJ?
NCI-H510A M4Pwb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17HbGlEPTB;NEeuPVA{PCEQvF2= NYG2dG1UW0GQR1XS
ML-2 NELpOJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NI[2cJpKSzVyPUS5Mlc5PTZizszN NHXS[2pUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo The oral bioavailability of ABT-888 is 56%-92% in mice, Sprague-Dawley rats, beagle dogs, and cynomolgus monkeys after oral administration. [1] ABT-888 (25 mg/kg i.p.) could improve tumor growth delay in a NCI-H460 xenograft model with well tolerated. Combination with radiation, ABT-888 decreases the tumor vessel formation. [3] ABT-888 reduces intratumor PAR levels by more than 95% at a dose of 3 and 12.5 mg/kg in A375 and Colo829 xenograft models and the suppression could be maintained over time. [4]

Protocol

Animal Research:

[1]

+ Expand
  • Animal Models: NCI-H460, H460, B16F10 and 9L xenografts in C57BL/6 mice
  • Formulation: Formulated in solution containing 0.9% NaCl adjusted to pH 4.0
  • Dosages: ~25 mg/kg
  • Administration: Orally administered
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 17 mg/mL (69.58 mM)
Water <1 mg/mL
Ethanol <1 mg/mL
In vivo 0.5% methylcellulose+0.2% Tween 80 5 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 244.29
Formula

C13H16N4O

CAS No. 912444-00-9
Storage powder
in solvent
Synonyms NSC 737664

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00553189 Completed Solid Tumors|Lymphomas National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) August 9, 2007 Phase 1
NCT03032614 Not yet recruiting Breast Cancer Stage IV|Ovarian Cancer|BRCA1 Mutation|BRCA2 Mutation The University of Texas Health Science Center at San Antonio March 31, 2017 Phase 2
NCT01445522 Completed Neoplasms|Lymphoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) December 3, 2008 Phase 1
NCT01419548 Withdrawn Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 29, 2011 Phase 1
NCT02723864 Recruiting Neoplasms National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) March 22, 2016 Phase 1
NCT00994071 Completed Medulloblastoma|Pontine Glioma|Ependymoma|Astrocytoma|PNET National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) September 22, 2009 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PARP Signaling Pathway Map

PARP Inhibitors with Unique Features

Related PARP Products

Tags: buy Veliparib (ABT-888) | Veliparib (ABT-888) supplier | purchase Veliparib (ABT-888) | Veliparib (ABT-888) cost | Veliparib (ABT-888) manufacturer | order Veliparib (ABT-888) | Veliparib (ABT-888) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID